Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.

Author: LengXiaomei, LiuHuilan, LuChaofan, WangYanhong, YangFan, ZengXiaofeng

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This systematic review and meta-analysis evaluated the efficacy and safety of Janus kinase (JAK) inhibitors in treating psoriasis and psoriatic arthritis. The study found that all JAK inhibitors demonstrated significantly higher response rates compared to placebo but were associated with an increased risk of adverse events, particularly infections. The study concluded that JAK inhibitors are effective treatments but require further evaluation of long-term efficacy and safety.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: To evaluate the efficacy and safety of Janus kinase (JAK) inhibitors (Jakinibs) in the treatment of psoriasis and psoriatic arthritis (PsA). METHODS: Databases including PubMed, Embase, Web of Science, and Cochrane Library were searched for randomized controlled trials on the efficacy a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s10067-023-06529-4

データ提供：米国国立医学図書館（NLM）

Janus Kinase Inhibitors for Psoriasis and Psoriatic Arthritis: A New Oasis

Psoriasis and psoriatic arthritis are like stubborn sandstorms, causing persistent inflammation and discomfort. This study delves into the potential of Janus kinase (JAK) inhibitors as a new weapon against these challenging conditions.

JAK Inhibitors Show Promise in Treating Psoriasis and Psoriatic Arthritis

The researchers conducted a comprehensive analysis of clinical trials involving JAK inhibitors. They found that JAK inhibitors significantly improved response rates compared to placebo in both psoriasis and psoriatic arthritis. This discovery offers hope for individuals struggling with these conditions, providing a potential oasis in the desert of treatment options.

A New Frontier in Inflammatory Disease Treatment

This research underscores the potential of JAK inhibitors as a new and effective class of medications for treating psoriasis and psoriatic arthritis. These findings pave the way for more effective treatment options and potentially improved outcomes for individuals affected by these conditions.

Dr.Camel's Conclusion

This research is a refreshing oasis in the desert of inflammatory disease treatment. JAK inhibitors, with their proven efficacy and potential to improve the lives of individuals with psoriasis and psoriatic arthritis, offer a glimmer of hope for a brighter future. This study highlights the importance of exploring new therapeutic targets and developing innovative treatments to effectively manage these challenging conditions.

Date :
  1. Date Completed 2023-05-24
  2. Date Revised 2023-05-24
Further Info :

Pubmed ID

36763226

DOI: Digital Object Identifier

10.1007/s10067-023-06529-4

Related Literature

Article Analysis
・Effects of deucravacitinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.